ALSV
AKRO

ATP Life Science Ventures’s Akero Therapeutics AKRO Stock Holding History

ATP Life Science Ventures’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,830,203
Closed -$169M – 1
2021
Q1 		$169M Hold
5,830,203
– – 18.83% 2
2020
Q4 		$168M Hold
5,830,203
– – 13.01% 2
2020
Q3 		$180M Buy
5,830,203
+415,000
+8% +$14.5M 24.2% 2
2020
Q2 		$135M Hold
5,415,203
– – 25.62% 2
2020
Q1 		$115M Hold
5,415,203
– – 23% 2
2019
Q4 		$120M Buy
+5,415,203
New +$112M 20.18% 2

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ATP Life Science Ventures's AKRO Position: Q2 2021 in Review

ATP Life Science Ventures sold out of Akero Therapeutics (AKRO) in Q2 2021, closing a stake of 5,830,203 shares — an estimated $169M sold.

ATP Life Science Ventures first reported a position in AKRO in Q4 2019 and held it in 6 quarters. The position peaked at $180M in Q3 2020. 97 funds tracked by Wall St. Rank hold AKRO as of Q2 2021.

  • ATP Life Science Ventures reported no remaining Akero Therapeutics position as of Q2 2021 after selling out during the quarter.
  • ATP Life Science Ventures sold 5,830,203 Akero Therapeutics shares in Q2 2021, an estimated $169M.
  • ATP Life Science Ventures first reported a position in Akero Therapeutics in Q4 2019 and held it in 6 quarters.
  • ATP Life Science Ventures's Akero Therapeutics position peaked at $180M in Q3 2020.
  • 97 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2021.

Based on ATP Life Science Ventures's 13F filing for Q2 2021.